Apnimed (APMD) Stock Price, News & Analysis

Company Overview

Apnimed Inc. is a clinical-stage pharmaceutical company focused on developing oral medicines for sleep apnea. The company is working to provide pharmacologic alternatives to device-based treatments for patients with obstructive sleep apnea, a condition involving repeated interruptions in breathing during sleep.

Apnimed’s lead candidate is AD109, an investigational once-daily combination of atomoxetine and aroxybutynine. The therapy is designed to improve the activity of muscles that help keep the upper airway open during sleep. AD109 has been evaluated in clinical studies involving adults with obstructive sleep apnea, including patients who may be unable or unwilling to use continuous positive airway pressure therapy.

The company’s operations have centered on clinical development and regulatory advancement in the United States, with its programs intended for potential use in broader sleep-medicine markets. Apnimed is headquartered in the United States and has been led by Chief Executive Officer Larry Miller. As an investigational pharmaceutical company, Apnimed does not yet have an approved commercial product.

Key Stats

• Today's Range: $21.49 to $24.50
• 50-Day Range: $21.09 to $32.55
• 52-Week Range: $16.12 to $35.29
• Volume: 668,811 shs
• Average Volume: 553,839 shs
• Market Capitalization: $912.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $50.33
• Consensus Rating: Moderate Buy

Apnimed Stock Analysis - MarketRank™

Apnimed scored higher than 70% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Apnimed has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Apnimed has a consensus price target of $50.33, representing about 129.7% upside from its current price of $21.91.

Amount of Analyst Coverage

Apnimed has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Apnimed are expected to decrease in the coming year, from ($0.24) to ($3.47) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.11% of the float of Apnimed has been sold short.

Short Interest Ratio / Days to Cover

Apnimed has a short interest ratio ("days to cover") of 3.24, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Apnimed has recently increased by 55.74%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Apnimed does not currently pay a dividend.

Dividend Growth

Apnimed does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.50

News Sentiment

Apnimed has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Apnimed this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for APMD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $5,000,000.00 in company stock, which represents 0.5482% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Apnimed insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,000,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

Apnimed has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 9/08/2026
• Today: 9/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:APMD
• CIK: 1745648
• Web: www.apnimed.com
• Phone: (617) 500-8880
• Fax: N/A
• Employees: 65
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Apnimed: $50.33
• High Price Target: $60.00
• Low Price Target: $41.00
• Potential Upside/Downside: +129.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.19
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $38.47 million
• Price / Sales: 23.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 41,630,000
• Free Float: N/A
• Market Cap: $912.11 million
• Optionable: N/A
• Beta: N/A